Following the publication of an opinion from the Superior Health Council, the Immunization Task Force recommends temporarily limiting immunizations to people between the ages of 18 and 55 using a product developed by AstraZeneca.
Pending receipt of additional data, the Superior Health Council (CSS) recommends temporarily restricting vaccination to people between the ages of 18 and 55 with a product developed by AstraZeneca, the Vaccination Task Force said on Friday, according to the CSS Opinion Publication. A second opinion suggests that AstraZeneca’s serum may be in the same condition as the Pfizer and Moderna vaccines given to pregnant women.
More data by March
This age range is due to a lack of data regarding the effectiveness of the AstraZeneca / Oxford vaccine in people over the age of 55, CSS says. “More data will likely be available by the end of March”, as the Phase 3 results of the AstraZeneca-Oxford US study and the effectiveness of the United Kingdom (where the elderly population received the vaccine from early January) should be available when the CSS is available. Is estimated
In this age group of 18 to 55 years, people with comorbidities can receive the British vaccine, the council continues. However, a messenger RNA type vaccine (Pfizer, Moderna) should be preferred for “solid and hematological” cancer patients presenting “severe immunodeficiency (pathology and / or treatment)”, particularly infectious diseases, transplants. Exposes patients or patients. Waiting lists, some patients with HIV infection or “rare diseases that require specific treatment by adenovirus-associated techniques”, ie the technique used by the AstraZeneca vaccine.
“In collaboration with hospitals, the immunization task force is difficult to ensure immunization coverage of these patients at risk. The aim is to provide them optimum protection against Kovid-19 and thus avoid them from hospitalization.
Regarding the interval between the administration of the two doses, the council recommends a minimum wait of eight and a maximum of 12 weeks after the first injection.
Finally, for pregnant women, with a desire to have a baby or while breastfeeding, the Superior Health Council remains on January 25 status: Vaccination through the product of AstraZeneca, Pfizer or Moderna is not recommended , But among those that may be considered. The benefits of vaccination, especially health workers such as the vaccine, outweigh the potential risks.